The UK and US have concluded a landmark bilateral deal that will preserve zero tariffs on UK pharmaceutical shipments being sold in the US market.
The Terms of the Deal
Under the terms of the agreement, the UK has committed to increase spending on pharmaceuticals through the NHS. This commitment guarantees that import taxes on these crucial products will remain at zero for a period of 36 months.
This development is in response to previous warnings to dramatically increase import taxes on branded drug imports, with figures mentioned up to double the cost.
"This arrangement with the Britain reinforces the worldwide climate for new treatments and establishes much-needed balance to American-British medicine commerce," an announcement said.
Economic Impact
Pharmaceuticals represent one of the the United Kingdom's largest goods shipped to the America, which is easily the biggest market for major companies like GSK and AstraZeneca.
Trade data show that in the 12 months prior to the third quarter, the UK sold drugs valued at £11.1bn to the US. This figure accounted for nearly one-fifth of total UK exports in that span.
"This guarantee secures work, increases funding and paves the way for the UK to emerge as a international leader for medical research," a minister commented.
Detailed UK Commitments
The agreement entails several notable commitments from the UK:
- Revised Affordability Limit: The UK will lift the price threshold at which it judges new medicines to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a aim to raise overall health service expenditure on medicines from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Refund Ceiling: The amount manufacturers must refund to the NHS to prevent overspending will be restricted at 15%. Last year, rebates topped twenty percent.
Recent Tensions
This agreement comes amid a long-running row between the pharmaceutical industry and the ministers over spending levels and regulatory access.
The disagreement were intensified by assertions that US patients were charged significantly more for the equivalent treatments than consumers in the other developed nations.
In recent months, several significant pharmaceutical investments in the UK have been paused or abandoned, while major funding commitments have been announced toward American operations.
A senior figure acknowledged that the NHS had to increase expenditure on medicines, noting that its expenditure on drugs had decreased as a share of its total funding over the last ten years.
